Results 251 to 260 of about 124,093 (287)
Some of the next articles are maybe not open access.
Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design, 2006Phosphodiesterase 5 inhibitors, such as sildenafil, vardenafil and tadalafil, are now approved for the treatment of erectile dysfunction. They inhibit the cGMP-specific isoform 5 of phosphodiesterase, resulting in cGMP accumulation, which, for example in smooth muscle cells, reduces muscular tone.
Thorsten, Reffelmann, Robert A, Kloner
openaire +2 more sources
Phosphodiesterase-5 inhibitors and their hemodynamic effects
Current Hypertension Reports, 2006Erectile dysfunction occurs commonly in untreated and treated hypertensive patients, impairing adherence to treatment and quality of life. Furthermore, it is a marker for enhanced risk for cardiovascular disease. Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, provide effective treatment of erectile dysfunction.
openaire +2 more sources
Key Features for Designing Phosphodiesterase-5 Inhibitors
Journal of Biomolecular Structure and Dynamics, 2010Phosphodiesterase superfamily is the key regulator of 3',5'-cyclic guanosine monophosphate (cGMP) decomposition in human body. Phosphodiesterase-5 (PDE-5) inhibitors, sildenafil, vardenafil and tadalafil, are well known oral treatment for males with erectile dysfunction.
Tung-Ti, Chang +7 more
openaire +2 more sources
The use of phosphodiesterase 5 inhibitors with concomitant medications
Journal of Endocrinological Investigation, 2008The phosphodiesterase-5 inhibitors (PDE5i) sildenafil, vardenafil, and tadalafil are considered first-line therapy for the treatment of patients with erectile dysfunction (ED). In addition to the classical pro-erectile-effect, clinical findings have suggested that they can also influence vascular tone in pulmonary, coronary and other vascular tissues ...
G. Corona +3 more
openaire +3 more sources
Advances in the development of phosphodiesterase 5 inhibitors
European Journal of Medicinal ChemistryPhosphodiesterase 5 (PDE5) can hydrolyze cyclic guanosine monophosphate (cGMP), which is critical for maintaining various physiological processes in organisms. Currently, clinically approved indications for PDE5 inhibitors encompass therapeutic agents for erectile dysfunction (ED), symptoms associated with lower urinary tract symptoms (LUTS), and ...
Tieqiang, Zong +8 more
openaire +2 more sources
The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology, 2006The oral phosphodiesterase type 5 (PDE5) inhibitors have made a valuable contribution to the treatment of erectile dysfunction (ED). PDE5 inhibitors enhance cavernosal smooth muscle relaxation, vasodilatation and penile erection. However, PDE5 inhibitors are not always effective.
David H W, Lau +5 more
openaire +2 more sources
Prescribing of Phosphodiesterase-5 Inhibitors Among Psychiatrists
Journal of Sex & Marital Therapy, 2013Phosphodiesterase-5 (PDE-5) inhibitors—avanafil, sildenafil, tadalafil, and vardenafil—are approved and widely used for treatment of erectile dysfunction of various etiologies.
Richard, Balon +2 more
openaire +2 more sources
Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors
Expert Opinion on Pharmacotherapy, 2011At the present time, inhibitors of phosphodiesterase type 5 (PDE5) have Food and Drug Administration approval only for the treatment of erectile dysfunction and pulmonary artery hypertension, for which their mechanism of action is vasodilation and augmentation of blood flow by impeding PDE5-mediated breakdown of cyclic guanosine monophosphate. However,
Robert A, Kloner +4 more
openaire +2 more sources
Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design, 2006Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothelial function and, erection is a ...
AVERSA, Antonio +3 more
openaire +3 more sources
In Defense of Phosphodiesterase 5 Inhibitors—Reply
JAMA Ophthalmology, 2022Mohit, Sodhi +2 more
openaire +2 more sources